Skip to main content
. 2014 Nov 26;56(2):305–314. doi: 10.1093/jrr/rru101

Fig. 1.

Fig. 1.

(a) Overall survival, (b) progression-free survival, and (c) local control of cervical cancer by treatment modality. Kaplan–Meier estimates of overall survival, progression-free survival, and local control in 52 patients with cervical cancer treated with nedaplatin-based concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy. Dashed lines represent 95% confidence intervals.